GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Up 139.4% in July

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 150,485 shares, an increase of 139.4% from the June 30th total of 62,850 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 266,107 shares, the short-interest ratio is currently 0.6 days.

GeoVax Labs Stock Performance

Shares of GOVX stock traded down $0.01 on Wednesday, hitting $0.72. 100,512 shares of the stock traded hands, compared to its average volume of 2,315,422. The firm’s 50-day moving average price is $1.50 and its two-hundred day moving average price is $1.80. The stock has a market capitalization of $2.50 million, a PE ratio of -0.04 and a beta of 3.68. GeoVax Labs has a twelve month low of $0.64 and a twelve month high of $20.62.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. On average, equities research analysts anticipate that GeoVax Labs will post -8.69 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

Several hedge funds have recently made changes to their positions in GOVX. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs during the 1st quarter valued at approximately $27,000. HRT Financial LP purchased a new position in GeoVax Labs in the fourth quarter worth approximately $31,000. Renaissance Technologies LLC purchased a new position in GeoVax Labs in the fourth quarter worth approximately $104,000. Finally, Armistice Capital LLC acquired a new stake in GeoVax Labs during the third quarter worth $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GOVX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.